Study of SyB C-1101 in Patients With Myelodysplastic Syndrome
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
To assess tolerability of SyB C-1101 when administered orally BID for 21 days followed by a
7-day observation period in patients with recurrent/relapsed or refractory myelodysplastic
syndrome in order to determine a recommended dose (RD). To assess safety, efficacy and
pharmacokinetics.